Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells $113,018.49 in Stock

Bioventus Inc. (NYSE:BVS - Get Free Report) CFO Mark Leonard Singleton sold 10,733 shares of the business's stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $10.53, for a total transaction of $113,018.49. Following the completion of the transaction, the chief financial officer now owns 105,162 shares in the company, valued at $1,107,355.86. This trade represents a 9.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Bioventus Stock Up 3.0 %

Shares of BVS stock traded up $0.32 on Thursday, reaching $11.00. 255,781 shares of the company were exchanged, compared to its average volume of 391,340. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The company has a 50-day moving average of $11.86 and a 200-day moving average of $9.77. The company has a market cap of $892.71 million, a price-to-earnings ratio of -18.03 and a beta of 0.79. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38.

Bioventus (NYSE:BVS - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The business had revenue of $138.96 million for the quarter, compared to analyst estimates of $132.57 million. During the same quarter in the prior year, the company earned $0.05 earnings per share. Analysts anticipate that Bioventus Inc. will post 0.41 earnings per share for the current year.

Institutional Trading of Bioventus

A number of hedge funds and other institutional investors have recently bought and sold shares of BVS. Squarepoint Ops LLC grew its holdings in shares of Bioventus by 13.8% during the second quarter. Squarepoint Ops LLC now owns 26,171 shares of the company's stock valued at $150,000 after buying an additional 3,170 shares during the last quarter. Virtus Fund Advisers LLC bought a new position in Bioventus in the 3rd quarter valued at about $42,000. Quest Partners LLC acquired a new position in Bioventus during the 3rd quarter valued at about $51,000. Quarry LP bought a new stake in Bioventus during the 3rd quarter worth approximately $59,000. Finally, Covestor Ltd purchased a new stake in shares of Bioventus in the third quarter worth approximately $69,000. Institutional investors own 62.94% of the company's stock.

Wall Street Analyst Weigh In

BVS has been the topic of a number of recent analyst reports. Canaccord Genuity Group boosted their price objective on Bioventus from $12.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. Craig Hallum boosted their price target on Bioventus from $12.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, September 27th. Finally, JPMorgan Chase & Co. raised shares of Bioventus from an "underweight" rating to a "neutral" rating and raised their price objective for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.